# Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus

> **NCT03986073** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** TQ-F3083 capsule 10 mg
- **DRUG:** TQ-F3083 capsule 20 mg
- **DRUG:** TQ-F3083 blank analog capsule
- **DRUG:** TQ-F3083 blank analog capsule
- **DRUG:** Linagliptin blank analog tablet
- **DRUG:** Linagliptin tablet

## Key facts

- **NCT ID:** NCT03986073
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-01
- **Primary completion:** 2020-06-30
- **Final completion:** 2020-09-30
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03986073

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03986073, "Study of TQ-F3083 Capsules in Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT03986073. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*